- Home
- SST vs CLDI Comparison
SST vs CLDI Comparison
Compare SST & CLDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SST
- CLDI
- Stock Information
- Founded
- SST 2013
- CLDI 2014
- Country
- SST United States
- CLDI United States
- Employees
- SST N/A
- CLDI N/A
- Industry
- SST Diversified Commercial Services
- CLDI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SST Consumer Discretionary
- CLDI Health Care
- Exchange
- SST Nasdaq
- CLDI Nasdaq
- Market Cap
- SST 23.3M
- CLDI 20.2M
- IPO Year
- SST N/A
- CLDI N/A
- Fundamental
- Price
- SST $5.74
- CLDI $5.02
- Analyst Decision
- SST Strong Buy
- CLDI
- Analyst Count
- SST 1
- CLDI 0
- Target Price
- SST $10.00
- CLDI N/A
- AVG Volume (30 Days)
- SST 59.2K
- CLDI 1.0M
- Earning Date
- SST 08-07-2025
- CLDI 08-08-2025
- Dividend Yield
- SST N/A
- CLDI N/A
- EPS Growth
- SST N/A
- CLDI N/A
- EPS
- SST N/A
- CLDI N/A
- Revenue
- SST $317,055,000.00
- CLDI N/A
- Revenue This Year
- SST N/A
- CLDI N/A
- Revenue Next Year
- SST $8.39
- CLDI N/A
- P/E Ratio
- SST N/A
- CLDI N/A
- Revenue Growth
- SST N/A
- CLDI N/A
- 52 Week Low
- SST $2.90
- CLDI $2.43
- 52 Week High
- SST $15.30
- CLDI $46.68
- Technical
- Relative Strength Index (RSI)
- SST 44.70
- CLDI 40.53
- Support Level
- SST $4.95
- CLDI $5.44
- Resistance Level
- SST $6.31
- CLDI $7.32
- Average True Range (ATR)
- SST 0.70
- CLDI 1.09
- MACD
- SST -0.18
- CLDI -0.45
- Stochastic Oscillator
- SST 23.06
- CLDI 0.00
About SST System1 Inc.
System1 Inc develops technology and data science to operate a responsive acquisition marketing platform. It serves customers in the areas of health and wellness, automotive, finance, travel, and entertainment. The company's segment includes Owned and Operated Advertising (O&O); and Partner Network. It generates maximum revenue from the Owned and Operated Advertising (O&O) segment. Geographically, it operates in United States and Other countries.
About CLDI Calidi Biotherapeutics Inc.
Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.